Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 2/20 | 0.60 |
| ▸ | OGG1 | O15527 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.42 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13356962 | 1.00 | PDE5A (0.60) | PDE5AOGG1TDP1L3MBTL1ATM | |
| SCHEMBL15820506 | 0.95 | PDE5A (0.54) | PDE5AOGG1TDP1L3MBTL1ATM | |
| SCHEMBL1369246 | 0.91 | OGG1 (0.53) | PDE5AOGG1TDP1L3MBTL1POLB | |
| SCHEMBL16404345 | 0.91 | OGG1 (0.53) | PDE5AOGG1TDP1L3MBTL1POLB | |
| SCHEMBL31052845 | 0.91 | OGG1 (0.53) | PDE5AOGG1TDP1L3MBTL1POLB | |
| SCHEMBL6337326 | 0.81 | HTR3A (0.43) | PDE5AOGG1POLBNTSR1KMT2A | |
| SCHEMBL4837936 | 0.80 | PDE5A (0.60) | PDE5AOGG1TDP1L3MBTL1ATM | |
| SCHEMBL4094738 | 0.76 | PDE5A (0.70) | PDE5AOGG1ADORA3TMEM97SIGMAR1 | |
| SCHEMBL4097329 | 0.75 | NTSR1 (0.62) | PDE5ATDP1L3MBTL1ATMLMNA | |
| SCHEMBL4259838 | 0.75 | NTSR1 (0.62) | PDE5ATDP1L3MBTL1ATMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7452912-B2 | Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-20040029873-A1 | Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2004-02-12 | — | — | US | disclosed |
| US-6545003-B1 | Treating asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. | ELAN PHARMACEUTICALS, INC. | 2003-04-08 | — | — | US | disclosed |
| CN-1336921-A | Fused ring heteroaryl and heterocyclic compounds that inhibit VLA-4 mediated leukocyte adhesion | ELAN PHARM INC (US) | 2002-02-20 | — | — | CN | disclosed |
| EP-1147091-A2 | FUSED RING HETEROARYL AND HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000043371-A2 | FUSED RING HETEROARYL AND HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029873-A1 | Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, LTB4R | PDE5A 4749/4885OGG1 4712/4885TDP1 4399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.